Polo-like kinase 1 (PLK1) is a serine/threonine kinase critical for regulating mitosis, including spindle formation, chromosome segregation, and cytokinesis . Overexpression of PLK1 is observed in ~80% of human cancers, making it a key target for oncology research and therapeutic development . The development of specific antibodies, such as the HRP-conjugated PLK1 antibody, has enabled precise detection and quantification of PLK1 in cellular contexts, facilitating mechanistic studies and drug discovery efforts.
The HRP-conjugated PLK1 antibody (ab203647) is a mouse monoclonal IgG2b antibody developed for Western blot (WB) applications . It targets the PLK1 protein in human samples, with reactivity confirmed in A431 and HEK293 cell lysates. The antibody is conjugated to horseradish peroxidase (HRP), enabling direct detection in WB without the need for secondary antibodies.
The antibody is optimized for Western blot analysis under reducing conditions. A representative WB experiment using A431 and HEK293 lysates demonstrated specific detection of PLK1 at 1:1000 dilution, with clear band visualization at 66 kDa (likely due to post-translational modifications) .
Lane | Sample | PLK1 Detection |
---|---|---|
1 | A431 lysate (10 µg) | Positive |
2 | HEK293 lysate (10 µg) | Positive |
PLK1 regulates mitotic progression by phosphorylating substrates such as BUB1B/BUBR1 and STAG2/SA2, ensuring proper kinetochore attachment and sister chromatid separation . Its overexpression in cancers correlates with aggressive tumor growth, highlighting its role as a therapeutic target .
The HRP-conjugated antibody has been used to study PLK1 localization and activity in contexts such as: